Jeffrey Matous, MD, shares updates on the TRIlogy-1 trial of ramantamig, a BCMA & GPRC5d trispecific antibody. Response was sustained in pts who switched to Q8W dosing; 2-year PFS was >80% in pts with BCMA/GPRC5d-naïve TCE RRMM. #IMS26
September 24, 2026 at 1:43 PM
Jeffrey Matous, MD, shares updates on the TRIlogy-1 trial of ramantamig, a BCMA & GPRC5d trispecific antibody. Response was sustained in pts who switched to Q8W dosing; 2-year PFS was >80% in pts with BCMA/GPRC5d-naïve TCE RRMM. #IMS26
Shari Kaiser, PhD, presents rationale, CAR design approach, preclinical efficacy data & examples of clinical response data in pts with diverse target profiles for investigational BCMA/GPRC5d dual-targeting CAR-T, BMS-986453. #IMS26
September 26, 2026 at 11:55 AM
Shari Kaiser, PhD, presents rationale, CAR design approach, preclinical efficacy data & examples of clinical response data in pts with diverse target profiles for investigational BCMA/GPRC5d dual-targeting CAR-T, BMS-986453. #IMS26
BCMA×GPRC5D dual-targeted CAR-T therapy BMS-986453 showed >90% response rates at two dose levels in ongoing first-in-human early-phase trial, w/ 100% response 100% MRD-negativity in BCMA/GPRC5d-naïve pts --- Doris Hansen, MD #IMS26
September 26, 2026 at 11:18 AM
BCMA×GPRC5D dual-targeted CAR-T therapy BMS-986453 showed >90% response rates at two dose levels in ongoing first-in-human early-phase trial, w/ 100% response 100% MRD-negativity in BCMA/GPRC5d-naïve pts --- Doris Hansen, MD #IMS26
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma @naturemedicine.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
January 17, 2026 at 5:37 AM
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma @naturemedicine.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
September 18, 2025 at 6:02 PM
Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
Does every pt need BCMA or GPRC5d at first relapse? CAR-T, bispecific, or ADC? What abt tx sequencing? Patient preferences? Dr. Mateos used practical questions to frame the discussion on clinical decision-making at first relapse. #IMS26
September 24, 2026 at 7:28 AM
Does every pt need BCMA or GPRC5d at first relapse? CAR-T, bispecific, or ADC? What abt tx sequencing? Patient preferences? Dr. Mateos used practical questions to frame the discussion on clinical decision-making at first relapse. #IMS26
A 63-year-old man developed a CAR-carrying T cell lymphoma post-therapy, revealing insights into clonal evolution and disease progression.
by Braun T, Rade M (...) Richardson T et 20 al. in Nat Med #MedSky
📖 read the article:
by Braun T, Rade M (...) Richardson T et 20 al. in Nat Med #MedSky
📖 read the article:
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody - Nature Medicine
A longitudinal multiomics analysis of a patient with multiple myeloma who developed peripheral T cell lymphoma after treatment with anti-BCMA CAR T cells and a GPRC5D-directed bispecific antibody reveals that two mutated CAR+CD8+ T cell clones were probably drivers of the neoplasm.
www.nature.com
March 2, 2025 at 6:36 PM
A 63-year-old man developed a CAR-carrying T cell lymphoma post-therapy, revealing insights into clonal evolution and disease progression.
by Braun T, Rade M (...) Richardson T et 20 al. in Nat Med #MedSky
📖 read the article:
by Braun T, Rade M (...) Richardson T et 20 al. in Nat Med #MedSky
📖 read the article:
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody | Nature Medicine
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody - Nature Medicine
A longitudinal multiomics analysis of a patient with multiple myeloma who developed peripheral T cell lymphoma after treatment with anti-BCMA CAR T cells and a GPRC5D-directed bispecific antibody reve...
www.nature.com
February 25, 2025 at 5:55 AM
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody | Nature Medicine
www.nature.com/articles/s41...
www.nature.com/articles/s41...
#ASH24 Phase I clinical trial of Anti-BCMA/GPRC5D bispecific CAR T-Cells in RRMM with Extramedullary Disease. N=6, ORR: 100% (CR: 50%) #mmsm #bmtsm ash.confex.com/ash/2024/web...
Paper: A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease
ash.confex.com
December 4, 2024 at 4:17 AM
#ASH24 Phase I clinical trial of Anti-BCMA/GPRC5D bispecific CAR T-Cells in RRMM with Extramedullary Disease. N=6, ORR: 100% (CR: 50%) #mmsm #bmtsm ash.confex.com/ash/2024/web...
Emerging Risk of Campylobacter spp. Infection Associated with Anti-BCMA and Anti-GPRC5D Bispecific Antibodies
✅ Just Accepted
🔗 https://bit.ly/3LsCGeP
✅ Just Accepted
🔗 https://bit.ly/3LsCGeP
November 9, 2025 at 9:14 PM
Emerging Risk of Campylobacter spp. Infection Associated with Anti-BCMA and Anti-GPRC5D Bispecific Antibodies
✅ Just Accepted
🔗 https://bit.ly/3LsCGeP
✅ Just Accepted
🔗 https://bit.ly/3LsCGeP
Silence of the myeloma clones: GPRC5D epigenetic regulation buff.ly/l8Xcld9 #hemesky
July 16, 2025 at 5:04 PM
Silence of the myeloma clones: GPRC5D epigenetic regulation buff.ly/l8Xcld9 #hemesky
Jing Li, MD, shares updated data for IBI3003, a novel BCMA×GPRC5d×CD3 trispecific antibody, in triple drug class-exposed pts with relapsed/refractory myeloma. ORR was 80%–85%, w/ 100% MRD-negativity, & efficacy also in pts w/ prior BCMA tx. #IMS26
September 26, 2026 at 11:16 AM
Jing Li, MD, shares updated data for IBI3003, a novel BCMA×GPRC5d×CD3 trispecific antibody, in triple drug class-exposed pts with relapsed/refractory myeloma. ORR was 80%–85%, w/ 100% MRD-negativity, & efficacy also in pts w/ prior BCMA tx. #IMS26
Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified
May 23, 2025 at 3:51 PM
Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified
What is GPRC5D? IMF Chief Medical Officer Dr. Joseph Mikhael explains this new way to attack myeloma in this short clip. Watch the full video at www.myeloma.org/node/11766 Supported by an educational grant from Janssen Biotech, Inc.
#IMFMyelomaMadeSimple
#IMFMyelomaMadeSimple
June 28, 2025 at 6:26 PM
What is GPRC5D? IMF Chief Medical Officer Dr. Joseph Mikhael explains this new way to attack myeloma in this short clip. Watch the full video at www.myeloma.org/node/11766 Supported by an educational grant from Janssen Biotech, Inc.
#IMFMyelomaMadeSimple
#IMFMyelomaMadeSimple
Antigen-negative escape is a key driver of relapse after GPRC5D CAR T-cell therapy in MM.
buff.ly/pY5QoJL #hemesky
buff.ly/pY5QoJL #hemesky
July 11, 2025 at 6:02 PM
Antigen-negative escape is a key driver of relapse after GPRC5D CAR T-cell therapy in MM.
buff.ly/pY5QoJL #hemesky
buff.ly/pY5QoJL #hemesky
Genomic and transcriptomic analysis of multiple myeloma samples shows mechanisms of antigen escape from the GPRC5D T cell engager talquetamab, including biallelic deletions, SNVs, insertions-deletions, and chromatin silencing https://www.nature.com/articles/s41591-025-04175-8
January 23, 2026 at 1:45 PM
Genomic and transcriptomic analysis of multiple myeloma samples shows mechanisms of antigen escape from the GPRC5D T cell engager talquetamab, including biallelic deletions, SNVs, insertions-deletions, and chromatin silencing https://www.nature.com/articles/s41591-025-04175-8
Murali Janakiraman, MD, shared data on pts treated sequentially w/ BCMA & GPRC5D therapies & a hepta-exposed subset, in the largest-to-date international cohort in the IMWG Immunotherapy Registry. #IMS26
September 23, 2026 at 3:41 PM
Murali Janakiraman, MD, shared data on pts treated sequentially w/ BCMA & GPRC5D therapies & a hepta-exposed subset, in the largest-to-date international cohort in the IMWG Immunotherapy Registry. #IMS26
Majority of multiple myeloma patients develop antigenic escape mechanisms against GPRC5D-targeted T cell therapies, thwarting durable remissions.
by Lee H, Ahn S (...) Bahlis NJ et 32 al. in Nat Med #MedSky
👉 get more here
📖 read the article:
by Lee H, Ahn S (...) Bahlis NJ et 32 al. in Nat Med #MedSky
👉 get more here
📖 read the article:
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma - Nature Medicine
Genomic and transcriptomic analysis of samples from patients with multiple myeloma, followed by in vitro validation, indicate mechanisms of antigen escape in response to GPRC5D T cell-engager talquetamab, including biallelic deletions, small nucleotide variants, insertion-deletions and chromatin silencing.
www.nature.com
January 24, 2026 at 4:47 AM
Llega talquetamab, primera terapia anti-GPRC5D al rescate del mieloma www.diariomedico.com/medicina/hem...
Llega talquetamab, primera terapia anti-GPRC5D al rescate del mieloma
'Talvey' es un anticuerpo biespecífico que logra prolongar la supervivencia en cuarta línea de tratamiento. Puede usarse antes y después de la terapia anti-BCMA.
www.diariomedico.com
December 8, 2024 at 8:05 PM
Llega talquetamab, primera terapia anti-GPRC5D al rescate del mieloma www.diariomedico.com/medicina/hem...
Starting soon at #IMS26: Dr. Juan-Jose Garces will present a new method to identify patients with GPRC5D-negative multiple myeloma with t(11;14) translocation, helping guide clinical decision making.
🗓️ Friday, September 25
🕐 12 p.m. BT (7 a.m. ET)
@mskcancercenter.bsky.social
🗓️ Friday, September 25
🕐 12 p.m. BT (7 a.m. ET)
@mskcancercenter.bsky.social
September 25, 2026 at 10:30 AM
Starting soon at #IMS26: Dr. Juan-Jose Garces will present a new method to identify patients with GPRC5D-negative multiple myeloma with t(11;14) translocation, helping guide clinical decision making.
🗓️ Friday, September 25
🕐 12 p.m. BT (7 a.m. ET)
@mskcancercenter.bsky.social
🗓️ Friday, September 25
🕐 12 p.m. BT (7 a.m. ET)
@mskcancercenter.bsky.social
The Expanding Market of GPRC5D-directed Therapies for Multiple Myeloma by 2034#United_States#Las_Vegas#DelveInsight#GPRC5D#Myeloma
The Expanding Market of GPRC5D-directed Therapies for Multiple Myeloma by 2034
DelveInsight predicts significant growth in the GPRC5D-directed therapies market for relapsed multiple myeloma, driven by innovative treatments and rising demand.
third-news.com
July 3, 2025 at 9:38 PM
The Expanding Market of GPRC5D-directed Therapies for Multiple Myeloma by 2034#United_States#Las_Vegas#DelveInsight#GPRC5D#Myeloma
JNJ-5322 Demonstrates Preliminary Efficacy and Is Safe in R/R Multiple Myeloma. #hematology #myeloma #ASCO25 @ascocancer.bsky.social
www.onclive.com/view/jnj-532...
www.onclive.com/view/jnj-532...
JNJ-5322 Demonstrates Preliminary Efficacy and Is Safe in R/R Multiple Myeloma
The trispecific antibody JNJ-5322 showed preliminary efficacy and safety signals in BCMA- and GPRC5D-naive relapsed/refractory myeloma.
www.onclive.com
June 26, 2025 at 9:51 PM
JNJ-5322 Demonstrates Preliminary Efficacy and Is Safe in R/R Multiple Myeloma. #hematology #myeloma #ASCO25 @ascocancer.bsky.social
www.onclive.com/view/jnj-532...
www.onclive.com/view/jnj-532...
Have the BCMA ones but I missed the GPRC5D ones
December 18, 2024 at 4:34 PM
Have the BCMA ones but I missed the GPRC5D ones